C4 Therapeutics, Inc. vs. Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| CCCC | HALO | |
|---|---|---|
| Market Cap | $417.06 million | $12.76 billion |
| Revenue (TTM) | $35.04 million | $1.66 billion |
| Net Income (TTM) | $-101,416,000 | $413.60 million |
HALO leads on 3 of 3 size & scale factors.
Valuation
| CCCC | HALO | |
|---|---|---|
| P/E Ratio | — | 32.78 |
| Price / Book | 1.69 | 88.91 |
| Price / Sales | 11.90 | 7.67 |
CCCC and HALO split the valuation factors evenly.
Profitability
| CCCC | HALO | |
|---|---|---|
| Net Margin | -289.44% | 24.86% |
| Return on Equity | -41.02% | 288.13% |
HALO leads on 2 of 2 profitability factors.
Risk & Sentiment
| CCCC | HALO | |
|---|---|---|
| Short Interest | 0.29% | 9.79% |
CCCC leads on 1 of 1 risk & sentiment factors.
Dig deeper: CCCC overview, CCCC financials, HALO overview, HALO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.